Latest Ampio Pharmaceuticals Inc. Stories
GREENWOOD VILLAGE, Colo., Oct 26, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced positive results of the Ampion(TM)-In-Knee (AIK) clinical trial. Michael Macaluso, Chairman of the Board, noted that, "In this first ever trial of Ampion(TM) in humans the drug was shown to be well tolerated and reduced pain over and...
GREENWOOD VILLAGE, Colo., Oct. 18, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has demonstrated in an IRB approved, randomized, placebo controlled, double-blinded proof of concept study, that low dose intranasal danazol has an impact on allergic rhinitis, a clinical condition in which increases in vascular...
GREENWOOD VILLAGE, Colo., Oct. 13, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has completed the treatment phase of the Ampion(TM)-in-Knee (AIK) trial. The AIK trial conducted in Australia included 60 patients with moderate to severe osteoarthritis of the knee. Results of this trial will be analyzed and...
GREENWOOD VILLAGE, Colo., Oct. 10, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced the acceptance for presentation at the American Association of Orthopedic Surgery (AAOS) meeting in February 2012 in San Francisco, CA of a publication describing a study of 22 patients undergoing surgical removal of orthopedic devices in...
GREENWOOD VILLAGE, Colo., Sept. 28, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has received notification of allowance of its two patent applications on Zertane(TM) combinations with erectile dysfunction (ED) drugs in Canada. This allowance includes claims directed to the use of Zertane(TM) with a class of...
GREENWOOD VILLAGE, Colo., Sept. 26, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced positive results from a 12-week open label extension study that was performed at the conclusion of the Phase III trials for Zertane(TM) in patients with premature ejaculation. No treatment-related serious adverse events and very...
GREENWOOD VILLAGE, Colo., Sept. 8, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced a license and development agreement with Daewoong Pharmaceuticals Co. Ltd., providing Daewoong Co. Ltd. exclusive rights to market Zertane(TM) in South Korea for the treatment of premature ejaculation (PE) and for a combination drug,...
GREENWOOD VILLAGE, Colo., Aug. 30, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that the manuscript reporting the results of its phase III clinical trials of Zertane(TM) for the treatment of the sexual dysfunction, premature ejaculation (PE), was accepted for publication in European Urology. Scientific Journal...
GREENWOOD VILLAGE, Colo., Aug. 22, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that Deborah Knobelman, Ph.D., has joined the management team as Chief Business Officer (CBO) reporting directly to Ampio CEO, Don Wingerter. Prior to joining Ampio, Dr. Knobelman spent three years at Pfizer, most recently as...
GREENWOOD VILLAGE, Colo., July 5, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs") today announced treatment of the first patient in the three-arm, placebo controlled, 60 patient Phase 1b Ampion-In -Knee (AIK) trial in Australia. The active ingredient in Ampion((TM) )has extensive worldwide patent protection including composition...
